Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

THYROCARE TECHNOLOGIES 2023-24 Annual Report Analysis
Mon, 5 Aug

THYROCARE TECHNOLOGIES has announced its results for the year ended March 2024. Let us have a look at the detailed performance review of the company during FY23-24.

THYROCARE TECHNOLOGIES Income Statement Analysis

  • Operating income during the year rose 8.6% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 12.5% YoY during the fiscal. Operating profit margins witnessed a fall and down at 24.3% in FY24 as against 23.5% in FY23.
  • Depreciation charges increased by 21.4% and finance costs increased by 14.5% YoY, respectively.
  • Other income grew by 11.2% YoY.
  • Net profit for the year grew by 8.0% YoY.
  • Net profit margins during the year declined from 12.2% in FY23 to 12.2% in FY24.

THYROCARE TECHNOLOGIES Income Statement 2023-24

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Net Sales Rs m 5,267 5,719 8.6%
Other income Rs m 84 94 11.2%
Total Revenues Rs m 5,351 5,812 8.6%
Gross profit Rs m 1,237 1,392 12.5%
Depreciation Rs m 387 470 21.4%
Interest Rs m 48 55 14.5%
Profit before tax Rs m 886 960 8.3%
Tax Rs m 242 265 9.3%
Profit after tax Rs m 644 695 8.0%
Gross profit margin % 23.5 24.3
Effective tax rate % 27.4 27.6
Net profit margin % 12.2 12.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Must See: These Segments are Witnessing Incredible Growth with Modi's Push

THYROCARE TECHNOLOGIES Balance Sheet Analysis

  • The company's current liabilities during FY24 stood at Rs 905 million as compared to Rs 771 million in FY23, thereby witnessing an increase of 17.4%.
  • Long-term debt stood at Rs 109 million as compared to Rs 0 million during FY23, a fall of 0.0%.
  • Current assets rose 2% and stood at Rs 3 billion, while fixed assets fell 28% and stood at Rs 4 billion in FY24.
  • Overall, the total assets and liabilities for FY24 stood at Rs 6 billion as against Rs 8 billion during FY23, thereby witnessing a fall of 17%.

THYROCARE TECHNOLOGIES Balance Sheet as on March 2024

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Networth Rs m 5,298 5,224 -1.4
 
Current Liabilities Rs m 771 905 17.4
Long-term Debt Rs m 0 109 0.0
Total Liabilities Rs m 7,610 6,291 -17.3
 
Current assets Rs m 2,729 2,785 2.0
Fixed Assets Rs m 4,881 3,506 -28.2
Total Assets Rs m 7,610 6,291 -17.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



THYROCARE TECHNOLOGIES Cash Flow Statement Analysis

  • THYROCARE TECHNOLOGIES's cash flow from operating activities (CFO) during FY24 stood at Rs 2 billion, an improvement of 29.6% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY24 stood at Rs -913 million, an improvement of 134.1% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY24 stood at Rs -848 million, an improvement of 2% on a YoY basis.
  • Overall, net cash flows for the company during FY24 stood at Rs -85 million from the Rs 41 million net cash flows seen during FY23.

THYROCARE TECHNOLOGIES Cash Flow Statement 2023-24

Particulars No. of months 12 12 % Change
Year Ending Mar-23 Mar-24
Cash Flow from Operating Activities Rs m 1,293 1,676 29.6%
Cash Flow from Investing Activities Rs m -390 -913 -
Cash Flow from Financing Activities Rs m -862 -848 -
Net Cash Flow Rs m 41 -85 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for THYROCARE TECHNOLOGIES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 13.1, an improvement from the EPS of Rs 12.2 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 773.6, stands at 53.7 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 7.8 times, while the price to sales ratio stands at 7.2 times.
  • The company's price to cash flow (P/CF) ratio stood at 26.2 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Sales per share (Unadj.) Rs 99.5 108.0
TTM Earnings per share Rs 12.2 13.1
Diluted earnings per share Rs 12.2 13.1
Price to Cash Flow x 22.1 26.2
TTM P/E ratio x 36.0 53.7
Price / Book Value ratio x 6.7 5.8
Market Cap Rs m 35,277 30,493
Dividends per share (Unadj.) Rs 0.0 0.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for THYROCARE TECHNOLOGIES

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 3.1x during FY24, from 3.5x during FY23. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 18.4x during FY24, from 19.3x during FY23. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 13.3% during FY24, from 12.1% during FY24. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 19.0% during FY24, from 17.6% during FY23. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 11.9% during FY24, from 9.1% during FY23. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Current ratio x 3.5 3.1
Debtors’ Days Days 6 3
Interest coverage x 19.3 18.4
Debt to equity ratio x 0.0 0.0
Return on assets % 9.1 11.9
Return on equity % 12.1 13.3
Return on capital employed % 17.6 19.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how THYROCARE TECHNOLOGIES has performed over the last 5 years, please visit here.

THYROCARE TECHNOLOGIES Share Price Performance

Over the last one year, THYROCARE TECHNOLOGIES share price has moved up from Rs 572.6 to Rs 773.6, registering a gain of Rs 201.0 or around 35.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 40,058.1 (down 1.8%). Over the last one year it has moved up from 27,852.0 to 40,058.1, a gain of 12,206 points (up 43.8%).

Overall, the S&P BSE SENSEX is up 18.6% over the year.

(To know more, check out historical annual results for THYROCARE TECHNOLOGIES and quarterly results for THYROCARE TECHNOLOGIES)

Annual Report FAQs

What is the current share price of THYROCARE TECHNOLOGIES?

THYROCARE TECHNOLOGIES currently trades at Rs 957.5 per share. You can check out the latest share price performance of THYROCARE TECHNOLOGIES here...

What was the revenue of THYROCARE TECHNOLOGIES in FY24? How does it compare to earlier years?

The revenues of THYROCARE TECHNOLOGIES stood at Rs 5,812 m in FY24, which was up 8.6% compared to Rs 5,351 m reported in FY23.

THYROCARE TECHNOLOGIES' revenue has grown from Rs 4,409 m in FY20 to Rs 5,812 m in FY24.

Over the past 5 years, the revenue of THYROCARE TECHNOLOGIES has grown at a CAGR of 7.2%.

What was the net profit of THYROCARE TECHNOLOGIES in FY24? How does it compare to earlier years?

The net profit of THYROCARE TECHNOLOGIES stood at Rs 695 m in FY24, which was up 8.0% compared to Rs 644 m reported in FY23.

This compares to a net profit of Rs 1,761 m in FY22 and a net profit of Rs 1,132 m in FY21.

Over the past 5 years, THYROCARE TECHNOLOGIES net profit has grown at a CAGR of -5.8%.

What does the cash flow statement of THYROCARE TECHNOLOGIES reveal?

The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.

This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.

The cash flow statement of THYROCARE TECHNOLOGIES reveals:

  • Cash flow from operations increased in FY24 and stood at Rs 1,676 m as compared to Rs 1,293 m in FY23.
  • Cash flow from investments decreased in FY24 and stood at Rs -913 m as compared to Rs -390 m in FY23.
  • Cash flow from financial activity increased in FY24 and stood at Rs -848 m as compared to Rs -862 m in FY23.

Here's the cash flow statement of THYROCARE TECHNOLOGIES for the past 5 years.

(Rs m)FY20FY21FY22FY23FY24
From Operations1,6791,1471,1341,2931,676
From Investments10-487-236-390-913
From Financial Activity-1,648-616-894-862-848
Net Cashflow4145441-85

What does the Key Ratio analysis of THYROCARE TECHNOLOGIES reveal?

Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.

The ratio/financial analysis of THYROCARE TECHNOLOGIES reveals:

  • Operating profit margins witnessed a fall and down at 24.3% in FY24 as against 23.5% in FY23.
  • Net profit margins declined from 12.2% in FY23 to 12.2% in FY24.
  • Debt to Equity ratio for FY24 stood at 0.0 as compared to 0.0 in FY23.

Here's the ratio/financial analysis of THYROCARE TECHNOLOGIES for the past 5 years.

 FY20FY21FY22FY23FY24
Operating Profit Margin (%)38.634.640.023.524.3
Net Profit Margin (%)20.422.929.912.212.2
Debt to Equity Ratio (x)0.00.00.00.00.0

Equitymaster requests your view! Post a comment on "THYROCARE TECHNOLOGIES 2023-24 Annual Report Analysis". Click here!